Location: Online, Virtual
Date: April 2 to April 4
Antithrombotic Approaches to Reduce the Risk of Secondary Event in CAD and PAD
Professor Marc Bonaca co-moderated a session at the American College of Cardiology meeting that was focused on the care of patients with advanced vascular disease. Specifictly diseases in the lower extremities, the legs and the arms called peripheral arterial disease.
Results from the EMPULSE Trial
Professor Mikhail Kosiborod going to speaking about the additional analysis from the EMPULSE trial that were presented at the American College of Cardiology congress. The trial demonstrated the effects of empagliflozin on symptoms, physical limitations and quality of life in patients hospitalized for acute heart failure.
Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk - The SCORED Trial
Professor Deepak Bhatt had presented an analysis from the SCORED trial at the American College of Cardiology Annual Sessions as a late-breaking clinical trial.
Bentracimab Immediately and Significantly Reverses the Antiplatelet Effects of Ticagrelor in Older People
Professor Deepak Bhatt gave us a brief recap of some data he presented at the ACC Late-Braker session. He presented data about a drug know as Bentracimab,which it is an investigational agent, a human monoclal antibody that it is been desigend to reverse the effect of the anti-platelet drug Ticagrelor.
Guidance in Heart Failure Care at ACC 2022
Professor David Lanfear summarize the key interesting things from the American College of Cardiology 2022 Scientific sessions in the topic.
How to reduce limb events including amputations in our patients?
Professor Manesh Patel speak about how to reduce limb events, amputations and making our patients limbs to better with peripheral arterial disease.
Updated Cumulative Results of Treatment With Mavacamten From the EXPLORER-LTE Cohort of the MAVA-LTE Study
Florian Rader presented this year at ACC 2022 the results of the MAVA-LTE Study. As the backdrop of this study, Hypertrophic Cardiomyopathy is a disease known for now over 70 years, and in these years we haven't had any specific medication that targets the underline mechanism of this disorder.